The company is backed by support from liver health researchers Dr. Naim Alkhouri and Dr. Naga Chalasani, and analysts maintain an $11 price target, indicating potential upside. This article was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback